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The penetration by moxifloxacin of human neutrophils (polymorphonuclear leukocytes [PMN]) and tissue-
cultured epithelial cells (McCoy cells) was evaluated by a fluorometric assay. At extracellular concentrations
of 5 mg/liter, the cellular-to-extracellular concentration ratios (C/E) of moxifloxacin in PMN and McCoy cells
were 10.9 6 1.0 and 8.7 6 1.0, respectively (20 min; 37°C). The uptake of moxifloxacin by PMN was rapid,
reversible, nonsaturable (at extracellular concentrations ranging from 1 to 50 mg/ml), and not affected by cell
viability. The uptake of moxifloxacin was affected by external pH and the environmental temperature. The
incubation of PMN in the presence of sodium fluoride, sodium cyanide, and carbonyl cyanide m-chlorophe-
nylhydrazone significantly decreased the C/E of this agent. Neither PMN stimulation nor phagocytosis of
opsonized Staphylococcus aureus significantly affected the uptake of moxifloxacin by human PMN. This agent,
at concentrations of 0.5, 1, and 5 mg/liter, induced a significant reduction in the survival of intracellular S.
aureus in human PMN. In summary, moxifloxacin reaches much higher intracellular concentrations within
phagocytic and nonphagocytic cells than extracellular ones, remaining active inside the neutrophils.
Fluoroquinolones are able to concentrate intracellularly in
human phagocytic cells, fibroblasts, and epithelial and endo-
thelial cells (10). Moreover, these agents are not affected by
the intracellular environment and remain active against differ-
ent facultative and obligate intracellular pathogens, such as
Staphylococcus aureus (1, 12), Legionella spp. (17), Mycobacte-
rium spp. (9), and Chlamydia spp. (7).
Moxifloxacin (BAY 12-8039) is a new 8-methoxyquinolone
with a bicyclic amine substituent at the 7 position and with a
broad spectrum of activity against both gram-negative and
gram-positive bacteria (2). Moxifloxacin has been found to be
2 to 16 times more active than ciprofloxacin and ofloxacin
against staphylococci, streptococci, enterococci, anaerobes,
and Chlamydia spp. (3, 6, 18).
The purpose of this study was to evaluate the uptake of
moxifloxacin by human polymorphonuclear leukocytes (PMN)
and tissue-cultured epithelial cells. The mechanism involved in
the penetration by this agent of human PMN and its intracel-
lular activity compared with those of ofloxacin and ciprofloxa-
cin were also evaluated.
MATERIALS AND METHODS
Isolation of PMN. PMN were recovered from heparinized venous blood of
healthy donors by using dextran sedimentation and a Ficoll-Hypaque gradient
and purified by previously described methods (16). PMN preparations were 97%
pure. Final cell suspensions were adjusted to 5 3 106 PMN per ml in Hanks
balanced salt solution (HBSS) containing 1% gelatin. PMN were 95% viable as
determined by trypan blue exclusion.
Tissue culture cells. McCoy cells (Flow Laboratories, Irvine, United King-
dom) were grown in minimal essential medium (Flow) supplemented with 1 mM
HEPES (Flow) and containing 10% fetal calf serum (Flow) without antibiotics.
For each experiment, the cells were detached from tissue culture bottles with
trypsin-EDTA (Flow), washed once with minimal essential medium containing
fetal calf serum (10%), and suspended in HBSS at a concentration of 5 3 106 per
ml.
Moxifloxacin uptake by cells. A previously described fluorometric assay was
used to measure quinolone uptake by human PMN and epithelial cells (11).
Moxifloxacin was kindly supplied by Bayer AG, Leverkusen, Germany. In these
experiments, PMN or tissue cells were incubated in HBSS containing different
concentrations of antimicrobial agent (1 to 50 mg/liter). After different incuba-
tion times at 37°C, cells were separated from the extracellular solution by cen-
trifugation through a water-impermeable silicone-oil barrier (density, 1,029
g/cm3) in a microcentrifuge tube. The entire cell pellet, obtained by cutting off
the portion of the microcentrifuge tube containing the pellet, was placed in 2 ml
of 0.1 M glycine-HCl buffer (pH 3.0) and agitated vigorously in a vortex shaker.
Incubation for 2 h at room temperature was sufficient to release the intracellular
antimicrobial agent fully (11). Samples were centrifuged for 5 min at 5,600 3 g,
and the amount of antimicrobial agent was determined by fluorescence emission
of supernatants with an F 2000 fluorescence spectrophotometer (Hitachi, Tokyo,
Japan). The fluorescence excitation and emission maxima in 0.1 M glycine-HCl
(pH 3.0) were 295 and 498 nm, respectively. Controls without antimicrobial
agents were always used to determine the background fluorescence.
Intracellular water space was measured by using tritiated water and the extra-
cellular marker [14C]polyethylene glycol (1.4 mCi/g; New England Nuclear
Corp., Boston, Mass.). Cells were incubated with these radiolabeled compounds
for 2 min at 37°C, separated from extracellular fluid by velocity gradient centrif-
ugation as described above, and counted in a liquid scintillation counter. Total
water content of the cell pellet was corrected for trapped extracellular water, i.e.,
polyethylene glycol space, to obtain the intracellular water space. From the
values obtained by this procedure, cell-associated antimicrobial agent concen-
trations were calculated and expressed as ratios of the cellular concentration to
extracellular concentration (C/E ratios) (8).
The efflux of reversibility of the binding of PMN or tissue cell-associated
moxifloxacin was also studied. Cells were incubated for 20 min at 37°C with
moxifloxacin (extracellular concentration, 5 mg/liter), collected by centrifuga-
tion, and rapidly suspended in quinolone-free medium. Cell-associated moxi-
floxacin was quantitated at various intervals (1, 5, 10, 20, and 30 min) after
removal of the extracellular antimicrobial agent. All assays were performed in
duplicate with PMN from five donors.
Characterization of moxifloxacin uptake. Further studies to elucidate the
mechanism of moxifloxacin uptake by PMN were performed as described pre-
viously (11). The importance of cell viability was studied by using PMN killed by
exposure to 10% formalin for 30 min. These cells were washed and then sus-
pended in fresh medium. Moreover, the influences of environmental tempera-
ture, pH, and metabolic inhibitors were evaluated. The influence of temperature
was examined by comparing antimicrobial uptake at 4 and 37°C. The pH profiles
of moxifloxacin uptake in media preadjusted to different external pHs (pH 5, 6,
7, and 8) by the addition of 10 N HCl or 10 N NaOH were measured. An
inhibitor of glycolysis (sodium fluoride, 1.5 3 1023 M) (Sigma Chemical Co., St.
Louis, Mo.), an inhibitor of mitochondrial oxidative metabolism (sodium cya-
nide, 1.5 3 1023 M) (Sigma), a blocker of the proton gradient (carbonyl cyanide
m-chlorophenylhydrazone [CCCP]; 1.5 3 1025 M) (Sigma), and an uncoupler of
oxidative phosphorylation (2,4-dinitrophenol; 1 3 1024 M) (Sigma) were used as
metabolic inhibitors. PMN in HBSS with and without metabolic inhibitors were
incubated for 30 min at 37°C. Moxifloxacin (final concentration, 5 mg/liter) was
then added, and the uptake was measured as described above.
In a series of experiments, moxifloxacin (extracellular concentration, 5 mg/
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liter) uptake by human PMN was measured after the stimulation of cells with 200
nM phorbol myristate acetate (PMA; Sigma) and after the phagocytosis of S.
aureus ATCC 25923 opsonized in 5% pooled human serum (15 min, 37°C) at a
10/1 ratio of bacteria to PMN. PMA or opsonized bacteria were added to PMN
suspensions at the same time as the antimicrobial agent, and the uptake was
measured as described above. Controls were always used to evaluate the effects
of inhibitors and substrates on the fluorescence of moxifloxacin in cell-free
systems. All assays were performed in duplicate with PMN from five different
donors.
Organisms and susceptibility testing. S. aureus ATCC 25923 was used for the
killing assays. Susceptibility studies were determined by dilution assay. The MICs
and minimum bactericidal concentrations of ciprofloxacin (Bayer AG), ofloxacin
(Hoechst AG), and moxifloxacin for this strain were 0.25, 0.25, and 0.06 mg/liter,
respectively.
Intracellular activity of antimicrobial agents. To evaluate the intracellular
activity of antimicrobial agents, a previously described method was used (15).
Briefly, 0.1 ml of bacterial suspension preopsonized in 5% pooled human serum
(5 3 107 CFU/ml) and 0.1 ml of PMN (5 3 106 per ml) were combined in a series
of polypropylene biovials (Beckman) and the vials were incubated in a shaker (50
rpm) for 60 min at 37°C. After incubation, the mixtures were washed three times
with 2.5 ml of ice-cold phosphate-buffered saline (pH 7.2) by using differential
centrifugation (160 3 g; 5 min at 4°C) to remove the extracellular bacteria. The
cells were then suspended in 0.2 ml of RPMI medium (Sigma). At this time
(designated time zero) different concentrations of the different fluoroquinolones
(0.125 to 5 mg/liter) were added, and the vials were reincubated in a shaker (50
rpm) at 37°C. The vials were removed at time zero (control without antimicrobial
agents) and after 3 h of incubation (control without antimicrobial agents and
samples with antimicrobial agents). Cells were lysed in distilled water, and
samples were diluted and pour plated in agar. Colonies were counted after 24 h
of incubation at 37°C. The data were expressed as percentages of staphylococci
surviving, compared with the levels in the controls (without antimicrobial agents)
at 3 h. In addition to determining bacterial survival, morphologic studies were
also routinely performed at time zero and after 3 h of incubation to evaluate the
disposition of bacteria (cell associated or extracellular). Samples (50 ml) were
removed from biovials and were deposited on glass slides. After being stained
with Wright stain, the samples were examined by light microscopy. All assays
were performed in duplicate with PMN from five different donors.
Statistical analysis of data. Data were expressed as means 6 standard devi-
ations. Differences among groups were compared by analysis of variance, used to
assess statistical significance at a P value of #0.05.
RESULTS
Uptake of moxifloxacin by PMN and tissue-cultured epithe-
lial cells. Figure 1 shows the kinetics of uptake of moxifloxacin
by both human PMN and tissue-cultured epithelial cells. Moxi-
floxacin uptake by these cells was rapid and high. With extra-
cellular concentrations of 5 mg/liter, the C/E ratios were higher
than 6 after 1 min of incubation. The kinetics of efflux of
moxifloxacin in both types of cells are also shown in Fig. 1. The
reversibility of binding of moxifloxacin was rapid, with 75 and
88% of the cell-associated drug being lost by 5 min in PMN and
McCoy cells, respectively.
The effect of extracellular concentrations of moxifloxacin on
uptake by PMN is presented in Fig. 2. Cell-associated moxi-
floxacin was not saturable at concentrations ranging from 1 to
50 mg/liter. Similar results were observed when McCoy cells
were used.
The effects of environmental temperature, cell viability, and
pH on the uptake of moxifloxacin by human PMN are shown
in Table 1. The intracellular penetration of moxifloxacin was
significantly impaired at 4°C but was not affected by cell via-
bility. The C/E values also decreased at pH 5, 6, and 8.
The effects of different metabolic inhibitors on moxifloxacin
uptake by human PMN are shown in Table 2. Among the
inhibitors evaluated, sodium fluoride, sodium cyanide, and
CCCP significantly impaired the intracellular penetration of
this quinolone. The stimulation of PMN by a membrane acti-
vator (PMA) and the phagocytosis of opsonized S. aureus did
not affect the intracellular penetration by moxifloxacin of PMN
(Table 2).
Intracellular activity of moxifloxacin against S. aureus. The
intracellular activity of moxifloxacin against S. aureus ATCC
25923 compared with those of ciprofloxacin and ofloxacin was
evaluated by a 3-h assay (Fig. 3). At extracellular concentra-
tions of 0.5, 1, and 5 mg/liter, moxifloxacin showed significant
intracellular activity against that microorganism compared to a
control without antimicrobial agents. This activity was similar
to that observed for ciprofloxacin and ofloxacin.
FIG. 1. Moxifloxacin uptake by both human PMN and McCoy cells and efflux
of cell-associated moxifloxacin after the removal of the extracellular drug
(n 5 5). The extracellular concentration was 5 mg/liter.
FIG. 2. Effect of extracellular concentrations on the intracellular penetration
of moxifloxacin in human PMN (n 5 5).
TABLE 1. Effect of environmental temperature, cell viability, and
external pH on the uptake of moxifloxacin by human PMN
Conditionsa C/E ratio
Viable cells at 37°C (control) .................................................10.9 6 1.0
Viable cells at 4°C .................................................................... 2.3 6 0.9b
Formalin-killed cells.................................................................11.1 6 1.4
pH 5 ........................................................................................... 7.2 6 0.2b
pH 6 ........................................................................................... 9.1 6 0.3
pH 7 ........................................................................................... 9.4 6 0.2
pH 8 ........................................................................................... 8.4 6 0.2b
a Experiments were carried out for 20 min at an extracellular concentration of
5 mg/liter with PMN from five subjects.
b P # 0.05 compared to viable cells at 37°C.
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The intracellular penetration by moxifloxacin of human
PMN and tissue-cultured epithelial cells was evaluated. At
therapeutic extracellular concentrations, moxifloxacin reached
intracellular concentrations in PMN 9 or more times higher
than extracellular ones. The C/E ratio of this quinolone was
slightly higher than those observed previously for ciprofloxacin,
ofloxacin, sparfloxacin, and other quinolones (4, 5, 12, 13).
Moxifloxacin also reached high intracellular concentrations
in tissue-cultured epithelial cells. These values are higher than
those observed for ofloxacin, levofloxacin, and lomefloxacin
and similar to those observed for trovafloxacin and sparfloxa-
cin (4, 12–14). The greater uptake of trovafloxacin and spar-
floxacin by these cells may be related to the higher hydropho-
bicity of these molecules, which allows them to cross the
cytoplasmic membranes more easily. This phenomenon, how-
ever, would not explain the high accumulation of moxifloxacin,
whose hydrophobicity is similar to that ofloxacin. Since moxi-
floxacin showed high intrinsic activity against Chlamydia spp.
and since these microorganisms can multiply within epithelial
cells, these results could reinforce the potential use of this
agent against chlamydial infections (18).
The penetration by moxifloxacin of human PMN was rapid,
nonsaturable, and reversible. In contrast to the case with most
quinolones, the uptake of moxifloxacin by PMN was signifi-
cantly decreased at acidic pHs (3, 4, 10, 13). This may be
related to the fact that this quinolone displays a bicyclic amine
and a metoxy substituent at the 7 and 8 positions, respectively.
The uptake of moxifloxacin was affected by environmental
temperature and some metabolic inhibitors, as has been de-
scribed for ofloxacin and BAY Y 3118 (5, 11). The uptake of
other quinolones, such as sparfloxacin and trovafloxacin, was
not affected by any of these parameters (4, 14). The mecha-
nisms whereby quinolones accumulate in cells are not yet
known, and no simple model can be presented in view of the
findings presented above. Although most data point towards a
passive mechanism, some are typical of an active one. Spar-
floxacin and trovafloxacin seem to use a passive mechanism,
probably related to their high hydrophobicities, which allow
easier penetration of cell membranes. Other less hydrophobic
quinolones, such as ofloxacin, BAY Y 3118, and moxifloxacin,
seem partially to require an active process. As has been de-
scribed previously for other quinolones (4, 14), neither the
phagocytosis of S. aureus nor the stimulation of the cell mem-
brane affected the intracellular accumulation of moxifloxacin
in PMN.
Moxifloxacin showed high intracellular activity against S.
aureus, similar to that of ciprofloxacin and ofloxacin. This ac-
tivity was dose dependent and probably related to intrinsic
activity against the strain used, its ability to concentrate within
phagocytes, and the fact that it is not affected by the intracel-
lular environment. Although the intrinsic activity of moxifloxa-
cin was superior to that of ciprofloxacin and ofloxacin, its
intracellular activity was only slightly higher than theirs. This
discrepancy could be related to different degrees of quinolone
activity in the intracellular compartment or to limitations in the
method of detecting differences of activity in compounds of-
fering very high intracellular activity.
In summary, moxifloxacin penetrates phagocytic and non-
phagocytic cells, reaching intracellular concentrations several
times higher than extracellular ones, while it remains active
intracellularly in human PMN. The high intracellular activity
of this agent and its broad spectrum of activity, in addition to
the properties observed in this study, enhance the potential
uses of moxifloxacin.
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